These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21163349)

  • 1. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
    Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
    Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
    Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
    Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
    Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
    J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
    Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
    J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.
    Barten DM; Fanara P; Andorfer C; Hoque N; Wong PY; Husted KH; Cadelina GW; Decarr LB; Yang L; Liu V; Fessler C; Protassio J; Riff T; Turner H; Janus CG; Sankaranarayanan S; Polson C; Meredith JE; Gray G; Hanna A; Olson RE; Kim SH; Vite GD; Lee FY; Albright CF
    J Neurosci; 2012 May; 32(21):7137-45. PubMed ID: 22623658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule microtubule-stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease.
    Yao Y; Muench M; Alle T; Zhang B; Lucero B; Perez-Tremble R; McGrosso D; Newman M; Gonzalez DJ; Lee VM; Ballatore C; Brunden KR
    Alzheimers Dement; 2024 Jul; 20(7):4540-4558. PubMed ID: 38884283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.
    Makani V; Zhang B; Han H; Yao Y; Lassalas P; Lou K; Paterson I; Lee VM; Trojanowski JQ; Ballatore C; Smith AB; Brunden KR
    Acta Neuropathol Commun; 2016 Sep; 4(1):106. PubMed ID: 27687527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
    Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
    Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
    Lou K; Yao Y; Hoye AT; James MJ; Cornec AS; Hyde E; Gay B; Lee VM; Trojanowski JQ; Smith AB; Brunden KR; Ballatore C
    J Med Chem; 2014 Jul; 57(14):6116-27. PubMed ID: 24992153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer's disease model.
    Fernandez-Valenzuela JJ; Sanchez-Varo R; Muñoz-Castro C; De Castro V; Sanchez-Mejias E; Navarro V; Jimenez S; Nuñez-Diaz C; Gomez-Arboledas A; Moreno-Gonzalez I; Vizuete M; Davila JC; Vitorica J; Gutierrez A
    Sci Rep; 2020 Sep; 10(1):14776. PubMed ID: 32901091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila.
    Xiong Y; Zhao K; Wu J; Xu Z; Jin S; Zhang YQ
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):4604-9. PubMed ID: 23487739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
    Brunden KR; Trojanowski JQ; Smith AB; Lee VM; Ballatore C
    Bioorg Med Chem; 2014 Sep; 22(18):5040-9. PubMed ID: 24433963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
    Brunden KR; Gardner NM; James MJ; Yao Y; Trojanowski JQ; Lee VM; Paterson I; Ballatore C; Smith AB
    ACS Med Chem Lett; 2013 Sep; 4(9):886-9. PubMed ID: 24900764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
    Ivashko-Pachima Y; Maor-Nof M; Gozes I
    PLoS One; 2019; 14(3):e0213666. PubMed ID: 30865715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.
    Zhang B; Maiti A; Shively S; Lakhani F; McDonald-Jones G; Bruce J; Lee EB; Xie SX; Joyce S; Li C; Toleikis PM; Lee VM; Trojanowski JQ
    Proc Natl Acad Sci U S A; 2005 Jan; 102(1):227-31. PubMed ID: 15615853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
    Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of microtubules improves cognitive functions and axonal transport of mitochondria in Alzheimer's disease model mice.
    Guo B; Huang Y; Gao Q; Zhou Q
    Neurobiol Aging; 2020 Dec; 96():223-232. PubMed ID: 33039900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.